{"result": "(\"entity\"<|>VAMIN® 14<|>ORGANIZATION<|>Vamin® 14 is a nitrogen solution used for parenteral nutrition, containing amino acids and nitrogen for adult patients.)\n##\n(\"entity\"<|>SINTAMIN® 17<|>ORGANIZATION<|>Sinthamin® 17 is a nitrogen solution for parenteral nutrition, providing essential amino acids and nitrogen.)\n##\n(\"entity\"<|>AMINO-PLASMA® L-15<|>ORGANIZATION<|>Amino-Plasmal® L-15 is a parenteral nitrogen solution with a high concentration of amino acids.)\n##\n(\"entity\"<|>TAURAMIN 12,6%<|>ORGANIZATION<|>Tauramin 12,6% is a nitrogen solution that includes taurine, used for parenteral nutrition.)\n##\n(\"entity\"<|>AMINO-PLASMA® PO 10<|>ORGANIZATION<|>Amino-Plasmal® PO 10 is a parenteral nutrition solution with a focus on amino acids and nitrogen.)\n##\n(\"entity\"<|>GLAMIN®<|>ORGANIZATION<|>Glamin® is a nitrogen solution for parenteral nutrition, rich in glutamine and essential amino acids.)\n##\n(\"entity\"<|>NEPHROMINE® 5,4%<|>ORGANIZATION<|>Nephromine® 5,4% is a specialized nitrogen solution for parenteral nutrition, designed for patients with kidney issues.)\n##\n(\"entity\"<|>AMINOSTERIL® N-HEPA 8%<|>ORGANIZATION<|>Aminosteril® N-Hepa 8% is a nitrogen solution for parenteral nutrition, focusing on amino acids and liver support.)\n##\n(\"entity\"<|>DIPEPTIVEN®<|>ORGANIZATION<|>Dipeptiven® is a nitrogen solution for parenteral nutrition, containing dipeptides for enhanced absorption.)\n##\n(\"entity\"<|>INTRALIPID® 30%<|>ORGANIZATION<|>Intralipid® 30% is a lipid solution used for parenteral nutrition, primarily composed of soybean oil.)\n##\n(\"entity\"<|>INTRALIPID® 20%<|>ORGANIZATION<|>Intralipid® 20% is a lipid solution for parenteral nutrition, also based on soybean oil.)\n##\n(\"entity\"<|>CLINOLEIC® 20%<|>ORGANIZATION<|>Clinoleic® 20% is a lipid solution for parenteral nutrition, containing a blend of oleic and soybean oils.)\n##\n(\"entity\"<|>LIPOFUNDINA® 10%<|>ORGANIZATION<|>Lipofundina® 10% is a lipid solution for parenteral nutrition, made from medium-chain triglycerides and soybean oil.)\n##\n(\"entity\"<|>LIPOFUNDINA® 20%<|>ORGANIZATION<|>Lipofundina® 20% is a lipid solution for parenteral nutrition, with a higher concentration of medium-chain triglycerides.)\n##\n(\"entity\"<|>LIPOPLUS® 20%<|>ORGANIZATION<|>Lipoplus® 20% is a lipid solution for parenteral nutrition, combining multiple lipid sources including omega-3.)\n##\n(\"entity\"<|>SMOFLIPID® 20%<|>ORGANIZATION<|>SMOFlipid® 20% is a lipid solution for parenteral nutrition, containing a mix of lipids including omega-3 fatty acids.)\n##\n(\"entity\"<|>OMEGAVEN®<|>ORGANIZATION<|>Omegaven® is a lipid solution for parenteral nutrition, rich in omega-3 fatty acids, used for specific medical conditions.)\n##\n(\"relationship\"<|>VAMIN® 14<|>SINTAMIN® 17<|>Both Vamin® 14 and Sinthamin® 17 are nitrogen solutions used for parenteral nutrition, indicating they serve similar purposes in medical nutrition therapy.<|>5)\n##\n(\"relationship\"<|>AMINO-PLASMA® L-15<|>TAURAMIN 12,6%<|>Both Amino-Plasmal® L-15 and Tauramin 12,6% are nitrogen solutions for parenteral nutrition, suggesting they are used in similar clinical settings.<|>5)\n##\n(\"relationship\"<|>GLAMIN®<|>NEPHROMINE® 5,4%<|>Glamin® and Nephromine® 5,4% are both nitrogen solutions for parenteral nutrition, with Glamin® being rich in glutamine and Nephromine® designed for kidney patients, indicating a relationship in their nutritional applications.<|>5)\n##\n(\"relationship\"<|>INTRALIPID® 30%<|>INTRALIPID® 20%<|>Both Intralipid® 30% and Intralipid® 20% are lipid solutions used for parenteral nutrition, indicating they are part of the same product line.<|>5)\n##\n(\"relationship\"<|>LIPOFUNDINA® 10%<|>LIPOFUNDINA® 20%<|>Lipofundina® 10% and Lipofundina® 20% are both lipid solutions for parenteral nutrition, with the latter having a higher concentration, indicating a direct relationship in their formulation.<|>5)\n##\n(\"relationship\"<|>LIPOPLUS® 20%<|>SMOFLIPID® 20%<|>Lipoplus® 20% and SMOFlipid® 20% are both lipid solutions for parenteral nutrition, suggesting they are used in similar therapeutic contexts.<|>5)\n##\n(\"relationship\"<|>OMEGAVEN®<|>SMOFLIPID® 20%<|>Omegaven® and SMOFlipid® 20% are both lipid solutions for parenteral nutrition, with Omegaven® specifically rich in omega-3 fatty acids, indicating a relationship in their nutritional benefits.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: |\n| Media ± ds | 39,5 ± 9,3 | 40,9 ± 9,6 | 21,3 ± 6,4 | 22,5 ± 6,7 |\n| Percentil 5,0 | 25,1 | 26,6 | 11,5 | 12,8 |\n| 10,0 | 28,0 | 29,2 | 12,6 | 14,0 |\n| 25,0 | 32,3 | 34,0 | 16,6 | 18,0 |\n| 50,0 | 38,0 | 40,0 | 21,3 | 22,0 |\n| 75,0 | 45,7 | 47,0 | 25,5 | 28,0 |\n| 90,0 | 52,5 | 54,0 | 30,1 | 31,1 |\n| 95,0 | 56,3 | 58,2 | 32,0 | 34,0 |\n\nSobre una muestra poblacional aleatoria de sujetos adultos sanos. ds: desviación estándar *Media de 3 determinaciones **Máxima puntuación obtenida.\n---\nThe image appears to be a blank white page. There is no visible content, text, diagrams, or any other information present in this image. Therefore, I cannot provide any markdown translation or description of content, as there is nothing to transcribe or describe.\n---\nAnexo 3.\nSoluciones nitrogenadas y lipídicas para nutrición\nparenteral\n\nTabla 1. Soluciones nitrogenadas de uso parenteral empleadas habitualmente en nuestro medio.\n\n| Producto | Vamin® 14 | Sinthamin® 17 | Amino-plasmal® L-15 | Tauramin 12,6% | Amino-Plasmal® PO 10 | Glamin® | Nephromine® 5,4% | Aminosteril® N-Hepa 8% | Dipeptiven® |\n|----------|-----------|----------------|---------------------|----------------|----------------------|---------|-------------------|------------------------|-------------|\n|          | AA estándares |              |                     | Con taurina    | Alto AARR            | Alto glutamina | Esenciales | Bajo AAAR Alto AARR | Alanin-Glutamina |\n| Volumen(ml) | 500     | 500            | 500                 | 500            | 500                  | 500     | 250               | 500                    | 100         |\n| Nitrógeno g/l | 13,5  | 16,5           | 24                  | 19,6           | 15                   | 22,4    | 6,5               | 12,9                   | 34,64       |\n| Aminoácidos g/l | 84  | 102            | 150                 | 122            | 96                   | 140     | 56                | 81                     | 216,6       |\n| Na mEq/l | -         | -               | 5,3                 | -              | -                    | -       | 6                 | -                      | -           |\n| Cl mEq/l | -         | 40              | -                   | 59             | 13,6                 | -       |                   | -                      | -           |\n| Acetato mEq/l | 90   | -               | -                   |                | 50,6                 | -       | 44                | -                      | -           |\n| Kcal/l   | 350       | 412             | 600                 | 385            | 400                  | 540     | 224               | 320                    | 866         |\n| Ph       | 5,6       | 6               | 5,7-6,3             |                | 5-7,5                | 5,8     | 6-7               | 5,7-6,3                | 5,4-6       |\n| mOsm/l   | 763       | 1060            | 1290                | 763            | 820                  | 1040    | 440               | 440                    | 921         |\n\nTabla 2. Soluciones lipídicas para uso parenteral empleadas habitualmente en nuestro medio.\n\n| Producto | Intralipid® 30% | Intralipid® 20% | Clinoleic® 20% | Lipofundina® 10% | Lipofundina® 20% | Lipoplus® 20% | SMOFlipid® 20% | Omegaven® |\n|----------|-----------------|-----------------|----------------|-------------------|-------------------|----------------|-----------------|-----------|\n| Composición | Soja | Soja | Oleico 80% Soja 20% | MCT Soja | MCT Soja | MCT, Soja Omega 3 | MCT, Soja, Oleico, Omega 3 | EPA 1,25-2,82 g DHA 1,44-3,09 g |\n| Presentaciones (ml) | 250, 333 | 100, 250, 500 | 100, 250, 350, 500, 1000 | 100, 250, 500 | 100, 250, 500 | 100, 250, 500, 1000 | 100, 250, 500 | 100 |\n|\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}